UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA
Clinical trials for UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo attack on biliary cancers: targeted drug plus chemo shows promise
Disease control OngoingThis study tests whether adding the targeted drug binimetinib to standard chemotherapy (mFOLFOX6) can shrink tumors or extend survival in people with advanced biliary tract cancers that have certain genetic changes (MAPK pathway alterations). About 66 participants whose cancer wo…
Matched conditions: UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo shows promise against tough bile duct cancer
Disease control OngoingThis phase 2 trial tests whether adding pevonedistat to standard chemotherapy (carboplatin and paclitaxel) can shrink tumors in people with advanced bile duct cancer that has spread or cannot be removed. About 40 adults whose cancer progressed after gemcitabine-based chemo will r…
Matched conditions: UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC